"HIV Integrase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA.
| Descriptor ID |
D019428
|
| MeSH Number(s) |
D27.505.519.389.375.400 D27.505.954.122.388.077.088.314
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Integrase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Integrase Inhibitors".
This graph shows the total number of publications written about "HIV Integrase Inhibitors" by people in this website by year, and whether "HIV Integrase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 18 | 10 | 28 |
| 2018 | 23 | 5 | 28 |
| 2019 | 13 | 2 | 15 |
| 2020 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Integrase Inhibitors" by people in Profiles.
-
CROI 2021: Epidemiologic Trends in the HIV and SARS-CoV-2 Pandemics and HIV Prevention Research. Top Antivir Med. 2021 Apr-May; 29(2):309-327.
-
COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. J Med Virol. 2021 03; 93(3):1796-1804.
-
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells. 2020 09 15; 9(9).
-
Highlights of AIDS 2020. Lancet HIV. 2020 08; 7(8):e532.
-
HIV drug resistance in a cohort of HIV-infected MSM in the United States. AIDS. 2020 01 01; 34(1):91-101.
-
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS. 2020 01 01; 34(1):103-108.
-
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother. 2019 11 01; 74(11):3295-3304.
-
Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals. Clin Infect Dis. 2019 09 27; 69(8):1320-1328.
-
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. J Antimicrob Chemother. 2019 09 01; 74(9):2742-2751.
-
Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R. N Engl J Med. 2019 08 29; 381(9):887-889.